Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal
Biocartis will use its expertise in molecular diagnostics to produce a companion diagnostic test for…
09/01/2018 - 1 minute
Amgen
Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy
Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both…
04/10/2017 - 2 minutes
Scottish Shark Antibodies have caught Amgen’s Eye
Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop…
09/05/2017 - 2 minutes
Novartis Negotiates its Way into the US Migraine Market
Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring…
25/04/2017 - 2 minutes
Meet One of the Most Successful German Biotech Leaders Ever
Patrick Baeuerle is the German biotech leader I wanted to interview the most (besides Simon…
17/04/2017 - 6 minutes
German Immuno-Oncology Biotech partners up with Biotech Giant Amgen
Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that…
09/01/2017 - 2 minutes
€36M Fundraising to Sequence the Genome of Ireland
Genomics Medicine Ireland (GMI) has raised €36M ($40M) in series A to sequence the genome of…
27/10/2016 - 2 minutes
€365M deal for a Danish ‘DNA barcode’ Drug Screening Platform
The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish…
05/10/2016 - 3 minutes
Italian Gene Therapy Biotech aims high by Collaborating with US Giant Amgen
Genenta Science and Amgen have teamed up to develop gene therapies for cancer. The Italian…
19/09/2016 - 2 minutes
German Biotech wins FDA Approval for New Liver Cancer Trial
4SC, in Germany, has the FDA's green light to conduct efficacy trials in the US…
24/02/2016 - 3 minutes
Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?
UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a…
22/02/2016 - 3 minutes
How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies
Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be…
01/12/2015 - 3 minutes
